1. Home
  2. EXFY vs MGNX Comparison

EXFY vs MGNX Comparison

Compare EXFY & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expensify Inc.

EXFY

Expensify Inc.

HOLD

Current Price

$1.38

Market Cap

132.1M

Sector

Technology

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.78

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXFY
MGNX
Founded
2008
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.1M
115.8M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
EXFY
MGNX
Price
$1.38
$1.78
Analyst Decision
Strong Buy
Hold
Analyst Count
1
5
Target Price
$4.50
$3.20
AVG Volume (30 Days)
446.5K
955.6K
Earning Date
02-26-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$143,907,000.00
$127,626,000.00
Revenue This Year
$4.44
N/A
Revenue Next Year
$0.56
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.71
N/A
52 Week Low
$1.30
$0.99
52 Week High
$4.00
$3.00

Technical Indicators

Market Signals
Indicator
EXFY
MGNX
Relative Strength Index (RSI) 45.30 49.06
Support Level $1.30 $1.66
Resistance Level $1.48 $1.97
Average True Range (ATR) 0.06 0.12
MACD -0.00 -0.02
Stochastic Oscillator 52.27 29.58

Price Performance

Historical Comparison
EXFY
MGNX

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: